Table 4. Cox proportional hazard models for overall survival.
| |
Unadjusted |
Adjusted |
||
|---|---|---|---|---|
| Parameter | HR (95% CI) | P-value | HR (95% CI) | P-value |
| NLR (⩾3 vs <3) |
1.80 (1.48–2.20) |
<0.001 |
1.67a (1.17–2.39) |
0.005 |
| Age |
1.03 (1.02–1.05) |
<0.001 |
1.01 (0.99–1.03) |
0.20 |
| Gender (female vs male) |
0.95 (0.81–1.11) |
0.48 |
0.89 (0.73–1.07) |
0.21 |
| Charlson Comorbidity Index |
1.28 (1.18–1.39) |
<0.001 |
1.23 (1.16–1.31) |
<0.001 |
| Haemoglobin (per 10 units) |
0.85 (0.82–0.87) |
<0.001 |
0.93 (0.89–0.97) |
<0.001 |
| Platelets (per 100 units) |
1.21 (1.11–1.31) |
<0.001 |
1.21 (1.14–1.28) |
<0.001 |
| T-stage (pT3–4 vs pT0–2) |
2.44 (1.58–3.77) |
<0.001 |
1.41 (0.82–2.42) |
0.21 |
| N-stage (N+ vs N0/Nx) |
2.22 (1.67–2.94) |
<0.001 |
1.59 (1.14–2.22) |
0.006 |
| Positive surgical margin |
2.00 (0.99–4.04) |
0.054 |
1.83 (0.94–3.60) |
0.078 |
| Year of radical cystectomy |
0.97 (0.93–1.01) |
0.15 |
0.95 (0.92–0.98) |
0.004 |
| Lymphovascular invasion |
2.65 (2.06–3.41) |
<0.001 |
2.08 (1.18–3.68) |
0.012 |
| NAC/primary chemotherapy |
1.44 (0.67–3.06) |
0.35 |
1.31 (0.81–2.13) |
0.28 |
| Adjuvant chemotherapy | 0.91 (0.62–1.33) | 0.61 | 0.84 (0.48–1.49) | 0.55 |
Abbreviations: CI=confidence interval; HR=hazard ratio; NAC=neo-adjuvant chemotherapy; NLR=neutrophil-to-lymphocyte ratio.
a
HR represents average HR across follow-up time. However, the HR varies as a function of time (see Figure 2 for details).